Literature DB >> 19403939

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

A Ravaud, M Sire.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19403939     DOI： 10.1093/annonc/mdp201

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  20 in total

Review 1.  Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging.

Authors:  Mohamed Bouattour; Audrey Payancé; Johanna Wassermann
Journal:  World J Hepatol       Date:  2015-09-18

Review 2.  Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.

Authors:  Koji Miyahara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.

Authors:  Brian C Boursiquot; Emily C Zabor; Ilya G Glezerman; Edgar A Jaimes
Journal:  Hypertension       Date:  2017-07-24       Impact factor: 10.190

4.  Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma.

Authors:  Ying Chen; Brian I Rini; Angel H Bair; Ganesh M Mugundu; Yazdi K Pithavala
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

5.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

Review 6.  Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib.

Authors:  Alessandro Granito; Sara Marinelli; Giulia Negrini; Saverio Menetti; Francesca Benevento; Luigi Bolondi
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 7.  Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.

Authors:  Alain Ravaud
Journal:  Oncologist       Date:  2011

Review 8.  Off-tumor target--beneficial site for antiangiogenic cancer therapy?

Authors:  Yihai Cao
Journal:  Nat Rev Clin Oncol       Date:  2010-08-03       Impact factor: 66.675

Review 9.  Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker.

Authors:  Emily S Robinson; Eliyahu V Khankin; S Ananth Karumanchi; Benjamin D Humphreys
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

10.  Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Authors:  Bruno Vincenzi; Daniele Santini; Antonio Russo; Raffaele Addeo; Francesco Giuliani; Liliana Montella; Sergio Rizzo; Olga Venditti; Anna Maria Frezza; Michele Caraglia; Giuseppe Colucci; Salvatore Del Prete; Giuseppe Tonini
Journal:  Oncologist       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.